Molnex (Morphine Hydrochloride Trihydrate)

Morphine Hydrochloride Trihydrate is an opioid analgesic that acts on the central nervous system to relieve pain.

• Severe acute pain: provides rapid, strong analgesia for patients with intense short‑term pain.
• Postoperative pain: reduces pain intensity after surgical procedures, facilitating recovery.
• Cancer pain: manages persistent malignant pain, improving quality of life.
• Chronic pain requiring opioid therapy: offers sustained analgesic effect for long‑term pain management under specialist supervision.

• Morphine Hydrochloride Trihydrate binds selectively to μ‑opioid receptors in the brain, spinal cord and peripheral nervous system. Activation of these G‑protein‑coupled receptors inhibits adenylate cyclase, reduces calcium influx and increases potassium efflux, leading to hyperpolarization of neurons and decreased transmission of nociceptive signals. This results in analgesia and sedation. The effect is dose‑dependent and can produce profound central nervous system depression at higher concentrations.

Morphine Hydrochloride Trihydrate may cause a range of adverse reactions, varying from common to serious.

Common Side Effects

• Nausea
• Constipation
• Drowsiness
• Dizziness
• Pruritus
• Dry mouth

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Allergic reactions including anaphylaxis

When using Morphine Hydrochloride Trihydrate, clinicians should observe several safety measures to minimize risk.

• Assess pain level and opioid tolerance: evaluate patient’s prior opioid exposure before initiating therapy.
• Monitor respiratory function: observe for signs of respiratory depression, especially after dose changes.
• Adjust dose in renal or hepatic impairment: reduce dosage or increase interval as needed.
• Avoid use with other central nervous system depressants: limit concurrent benzodiazepines or alcohol.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Morphine Hydrochloride Trihydrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other opioids: risk of additive respiratory depression.
• MAO inhibitors: can precipitate severe hypertension or serotonin syndrome.
• CNS depressants (benzodiazepines, barbiturates, alcohol): heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase morphine plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Diuretics (e.g., furosemide): can potentiate hypotensive effects.